Naldemedine + Placebo

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Postoperative Gastrointestinal Dysfunction

Conditions

Postoperative Gastrointestinal Dysfunction

Trial Timeline

Nov 6, 2020 → Jan 4, 2021

NCT ID

NCT04355169

About Naldemedine + Placebo

Naldemedine + Placebo is a phase 2 stage product being developed by Shionogi for Postoperative Gastrointestinal Dysfunction. The current trial status is terminated. This product is registered under clinical trial identifier NCT04355169. Target conditions include Postoperative Gastrointestinal Dysfunction.

What happened to similar drugs?

20 of 20 similar drugs in Postoperative Gastrointestinal Dysfunction were approved

Approved (20) Terminated (3) Active (0)

✅Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVEisaiApproved

✅EsomeprazoleAstraZenecaApproved

✅Aprepitant, Dexamethasone, Ondansetron + Aprepitant, Dexamethasone, PlaceboMerckApproved

✅Sugammadex + NeostigmineMerckApproved

✅Aprepitant + Dexamethasone + Ondansetron + DexamethasoneMerckApproved

✅Suvorexant + PlaceboMerckApproved

✅Aprepitant plus Ondansetron + Ondansetron plus placeboMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07038551	Approved	Recruiting	Jun 6, 2025	Sep 30, 2027	Opioid-Induced Constipation (OIC)
NCT04355169	Phase 2	Terminated	Nov 6, 2020	Jan 4, 2021	Postoperative Gastrointestinal Dysfunction
NCT01993940	Phase 3	Completed	Nov 4, 2013	Jun 9, 2015	Opioid-induced Constipation
NCT01965652	Phase 3	Completed	Sep 24, 2013	Jan 12, 2016	Opioid-induced Constipation
NCT01965158	Phase 3	Completed	Aug 29, 2013	Jan 22, 2015	Opioid-induced Constipation
NCT01122030	Phase 2	Completed	May 19, 2010	Mar 22, 2011	Opioid Induced Bowel Dysfunction

Competing Products

20 competing products in Postoperative Gastrointestinal Dysfunction

See all competitors

Product	Company	Stage	Hype Score
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IV	Eisai	Approved	43
Lemborexant 5 mg + Control (placebo) group	Eisai	Phase 2	42
Ondansetron + Palonosetron	Eisai	Phase 2	35
AQUAVAN (fospropofol disodium; GPI 15715 )	Eisai	Phase 2	35
ONO-1101	Ono Pharmaceutical	Phase 2	35
ONO-1101	Ono Pharmaceutical	Phase 2/3	38
Levofloxacin Ophthalmic + Cefuroxime	Santen Pharmaceutical	Phase 1/2	28
Levofloxacin Ophthalmic Product + Moxifloxacin Ophthalmic Solution	Santen Pharmaceutical	Phase 1/2	28
Bupivacaine Liposome Injection T preparation + Bupivacaine Liposome Injection R preparation	Jiangsu Hengrui Medicine	Phase 1	29
SHR0410 Injection + SHR0410 Injection + Placebo	Jiangsu Hengrui Medicine	Phase 3	36
SHR8554 Injection	Jiangsu Hengrui Medicine	Phase 1	29
Esomeprazole	AstraZeneca	Approved	43
deep neuromuscular block	Merck	Pre-clinical	26
Rolapitant Dose 1 + Rolapitant Dose 2 + Rolapitant Dose 3 + Rolapitant Dose 4 + Ondansetron + Placebo	Merck	Phase 2	35
MK0966, rofecoxib + Comparator: valdecoxib	Merck	Phase 3	40
Aprepitant, Dexamethasone, Ondansetron + Aprepitant, Dexamethasone, Placebo	Merck	Approved	43
MK0719	Merck	Phase 2	27
Sugammadex + Neostigmine	Merck	Approved	43
MK0869, aprepitant + Comparator: ondansetron IV	Merck	Phase 3	40
MK0869, aprepitant + Comparator: ondansetron IV	Merck	Phase 3	40